Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21744696 | 0.78 | CD44 (0.45) | CXCR4TLR9TLR7CYP2D6 | |
| SCHEMBL21744697 | 0.77 | CD44 (0.46) | TLR9TLR7CYP2D6CYP3A4 | |
| SCHEMBL21743788 | 0.77 | TLR9 (0.38) | CXCR4TLR9TLR7CYP2D6CHRM2 | |
| SCHEMBL16485203 | 0.69 | CD44 (0.50) | TLR9TLR7 | |
| SCHEMBL21744420 | 0.67 | CD44 (0.47) | CXCR4TLR9TLR7CYP2D6 | |
| SCHEMBL21743766 | 0.66 | CXCR4 (0.49) | CXCR4TLR9TLR7CYP2D6CYP3A4 | |
| SCHEMBL21744260 | 0.66 | CD44 (0.46) | CXCR4TLR9TLR7CYP2D6CYP3A4 | |
| SCHEMBL21743760 | 0.65 | TLR9 (0.49) | CXCR4TLR9TLR7CHRM2CHRM4 | |
| SCHEMBL21744610 | 0.65 | CD44 (0.45) | CXCR4TLR9TLR7CYP2D6 | |
| SCHEMBL21744394 | 0.64 | HTR2C (0.54) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885TLR9 138/4885TLR7 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.